{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T22:31:11Z","timestamp":1792621871924,"version":"4.5.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"vor","delay-in-days":2,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Discov Onc"],"DOI":"10.1007\/s12672-026-05009-w","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T06:52:59Z","timestamp":1778741579000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Overexpression of TREM1 predicts poor prognosis and chemotherapy resistance in Egyptian acute myeloid leukemia associated with FLT3 internal tandem duplication and CD123 expression and stemness signatures"],"prefix":"10.1007","volume":"17","author":[{"given":"Shima Gafar","family":"Mansor","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha","family":"Elgamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mostafa F. Mohammed","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8191-0035","authenticated-orcid":false,"given":"Amira A. A.","family":"Othman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Nawar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"12","key":"5009_CR1","first-page":"1345","volume":"140","author":"H D\u00f6hner","year":"2022","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR, Craddock C, DiNardo CD, Dombret H, Ebert BL, Fenaux P, Godley LA, Hasserjian RP, Larson RA. Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. Blood J Am Soc Hematol. 2022;140(12):1345\u201377.","journal-title":"Blood J Am Soc Hematol"},{"issue":"1","key":"5009_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/s13039-022-00621-1","volume":"15","author":"MG Elnaggar","year":"2022","unstructured":"Elnaggar MG, Mosad E, Makboul A, Shafik EA. Cytogenetic profile of adult acute myeloid leukemia in Egypt: a single-center experience. Mol Cytogenet. 2022;15(1):43.","journal-title":"Mol Cytogenet"},{"issue":"3","key":"5009_CR3","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jnci.2013.02.002","volume":"25","author":"N Kassem","year":"2013","unstructured":"Kassem N, Fahmy AE, Desoky M, Medhat N, Zawam HM. CCAAT\/enhancer binding protein \u03b1 gene expression in Egyptian patients with acute myeloid leukemia. J Egypt Natl Cancer Inst. 2013;25(3):115\u201320.","journal-title":"J Egypt Natl Cancer Inst"},{"key":"5009_CR4","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DiNardo CD, Kadia TM, Daver NG, Altman JK, Stein EM, Jabbour E, Schiffer CA, Lang A, Ravandi F. Acute myeloid leukemia management and research in 2025. CA: A Cancer Journal for Clinicians. 2025;75(1):46\u201367.","DOI":"10.3322\/caac.21873"},{"issue":"5","key":"5009_CR5","doi-asserted-by":"publisher","first-page":"503","DOI":"10.6004\/jnccn.2023.0025","volume":"21","author":"DA Pollyea","year":"2023","unstructured":"Pollyea DA, Altman JK, Assi R, Bixby D, Fathi AT, Foran JM, Gojo I, Hall AC, Jonas BA, Kishtagari A, Lancet J. Acute myeloid leukemia, version 3.2023, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2023;21(5):503\u201313.","journal-title":"J Natl Compr Canc Netw"},{"issue":"1","key":"5009_CR6","first-page":"71","volume":"127","author":"EM Stein","year":"2016","unstructured":"Stein EM, Tallman MS, Blood. J Am Soc Hematol. 2016;127(1):71\u20138.","journal-title":"J Am Soc Hematol"},{"issue":"2","key":"5009_CR7","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1038\/s41375-018-0357-9","volume":"33","author":"N Daver","year":"2019","unstructured":"Daver N, Schlenk RF, Russell NH, Levis MJ. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33(2):299\u2013312.","journal-title":"Leukemia"},{"key":"5009_CR8","doi-asserted-by":"publisher","first-page":"627","DOI":"10.3389\/fmicb.2014.00627","volume":"5","author":"K Roe","year":"2014","unstructured":"Roe K, Gibot S, Verma S. Triggering receptor expressed on myeloid cells-1 (TREM-1): a new player in antiviral immunity? Front Microbiol. 2014;5:627.","journal-title":"Front Microbiol"},{"issue":"16","key":"5009_CR9","doi-asserted-by":"publisher","first-page":"3977","DOI":"10.1158\/0008-5472.CAN-12-0938","volume":"72","author":"J Wu","year":"2012","unstructured":"Wu J, Li J, Salcedo R, Mivechi NF, Trinchieri G, Horuzsko A. The proinflammatory myeloid cell receptor TREM-1 controls Kupffer cell activation and development of hepatocellular carcinoma. Cancer Res. 2012;72(16):3977\u201386.","journal-title":"Cancer Res"},{"issue":"7","key":"5009_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1164\/rccm.200704-641OC","volume":"177","author":"CC Ho","year":"2008","unstructured":"Ho CC, Liao WY, Wang CY, Lu YH, Huang HY, Chen HY, Chan WK, Chen HW, Yang PC. TREM-1 expression in tumor-associated macrophages and clinical outcome in lung cancer. Am J Respir Crit Care Med. 2008;177(7):763\u201370.","journal-title":"Am J Respir Crit Care Med"},{"issue":"711","key":"5009_CR11","doi-asserted-by":"publisher","first-page":"eadd9990","DOI":"10.1126\/scitranslmed.add9990","volume":"15","author":"V Juric","year":"2023","unstructured":"Juric V, Mayes E, Binnewies M, Lee T, Canaday P, Pollack JL, Rudolph J, Du X, Liu VM, Dash S, Palmer R. TREM1 activation of myeloid cells promotes antitumor immunity. Sci Transl Med. 2023;15(711):eadd9990.","journal-title":"Sci Transl Med"},{"issue":"21","key":"5009_CR12","doi-asserted-by":"publisher","first-page":"4951","DOI":"10.1182\/blood.V122.21.4951.4951","volume":"122","author":"H Li","year":"2013","unstructured":"Li H, Li W, Yi X, Huang S, Liu W, Jiang L, Yang C, Li J. Differential expression of TREM-1 in myelogenous leukemia cells. Blood. 2013;122(21):4951.","journal-title":"Blood"},{"key":"5009_CR13","doi-asserted-by":"crossref","unstructured":"Ajith A, Mamouni K, Horuzsko DD, Musa A, Dzutsev AK, Fang JR, Chadli A, Zhu X, Lebedyeva I, Trinchieri G, Horuzsko A. Targeting TREM1 augments antitumor T cell immunity by inhibiting myeloid-derived suppressor cells and restraining anti\u2013PD\u20131 resistance. J Clin Investig. 2023;133(21).","DOI":"10.1172\/JCI167951"},{"key":"5009_CR14","doi-asserted-by":"crossref","unstructured":"Moualla Y, Moassass F, Bassel AH, Al-Achkar W, Georgeos M, Yazigi H, Khamis A. Evaluating the clinical significance of FLT3 mutation status in Syrian newly diagnosed acute myeloid leukemia patients with normal karyotype. Heliyon. 2022;8(11):e11858.","DOI":"10.1016\/j.heliyon.2022.e11858"},{"issue":"1","key":"5009_CR15","first-page":"437971","volume":"2014","author":"AS Ibrahim","year":"2014","unstructured":"Ibrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in Egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014(1):437971.","journal-title":"J Cancer Epidemiol"},{"issue":"9","key":"5009_CR16","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41571-021-00509-w","volume":"18","author":"H D\u00f6hner","year":"2021","unstructured":"D\u00f6hner H, Wei AH, L\u00f6wenberg B. Towards precision medicine for AML. Nat reviews Clin Oncol. 2021;18(9):577\u201390.","journal-title":"Nat reviews Clin Oncol"},{"key":"5009_CR17","doi-asserted-by":"crossref","unstructured":"Jiang G, Atenafu EG, Capo-Chichi JM, Minden MD, Chang H. Prognostic relevance of CD123 expression in adult AML with normal karyotype. Br J Haematol. 2020;188(1).","DOI":"10.1111\/bjh.16307"},{"issue":"1","key":"5009_CR18","doi-asserted-by":"publisher","first-page":"14870","DOI":"10.1038\/s41598-017-14516-4","volume":"7","author":"L Saurer","year":"2017","unstructured":"Saurer L, Zysset D, Rihs S, Mager L, Gusberti M, Simillion C, Lugli A, Zlobec I, Krebs P, Mueller C. TREM-1 promotes intestinal tumorigenesis. Sci Rep. 2017;7(1):14870.","journal-title":"Sci Rep"},{"key":"5009_CR19","doi-asserted-by":"crossref","unstructured":"Chow SC, Shao J, Wang H, Lokhnygina Y. Sample size calculations in clinical research. chapman and hall\/CRC; 2017. Aug 15.","DOI":"10.1201\/9781315183084"},{"issue":"3","key":"5009_CR20","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1158\/2159-8290.CD-18-0774","volume":"9","author":"N Daver","year":"2019","unstructured":"Daver N, Garcia-Manero G, Basu S, Boddu PC, Alfayez M, Cortes JE, Konopleva M, Ravandi-Kashani F, Jabbour E, Kadia T, Nogueras-Gonzalez GM. Efficacy, safety, and biomarkers of response to azacitidine and nivolumab in relapsed\/refractory acute myeloid leukemia: a nonrandomized, open-label, phase II study. Cancer Discov. 2019;9(3):370\u201383.","journal-title":"Cancer Discov"},{"issue":"S1","key":"5009_CR21","doi-asserted-by":"publisher","first-page":"S5","DOI":"10.1002\/cyto.b.20365","volume":"72","author":"BH Davis","year":"2007","unstructured":"Davis BH, Holden JT, Bene MC, Borowitz MJ, Braylan RC, Cornfield D, Gorczyca W, Lee R, Maiese R, Orfao A, Wells D. 2006 Bethesda International Consensus recommendations on the flow cytometric immunophenotypic analysis of hematolymphoid neoplasia: medical indications. Cytometry Part B: Clin Cytometry: J Int Soc Anal Cytol. 2007;72(S1):S5\u201313.","journal-title":"Cytometry Part B: Clin Cytometry: J Int Soc Anal Cytol"},{"key":"5009_CR22","unstructured":"Wayne PA. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing. 2015."},{"issue":"5","key":"5009_CR23","first-page":"529","volume":"67","author":"N Alaa El-Deen","year":"2024","unstructured":"Alaa El-Deen N, Dokla EM, Jaballah MY, Abouzid K, Serya RA. AML and FLT3: An Update on FDA-approved or Under Review Kinase Inhibitors Targeting FLT3 Kinase. Egypt J Chem. 2024;67(5):529\u201353.","journal-title":"Egypt J Chem"},{"key":"5009_CR24","doi-asserted-by":"crossref","unstructured":"Yuxi F, Ye X, Zhi H, Hedong Z, Longkai P, Xin J, Helong D. Role of triggering receptor expressed on myeloid cells-1 in kidney diseases: A biomarker and potential therapeutic target. Chin Med J. 2024;137:1663-73.","DOI":"10.1097\/CM9.0000000000003197"},{"key":"5009_CR25","doi-asserted-by":"publisher","first-page":"160940692312057","DOI":"10.1177\/16094069231205789","volume":"22","author":"M Naeem","year":"2023","unstructured":"Naeem M, Ozuem W, Howell K, Ranfagni S. A step-by-step process of thematic analysis to develop a conceptual model in qualitative research. Int J qualitative methods. 2023;22:16094069231205789.","journal-title":"Int J qualitative methods"},{"issue":"9","key":"5009_CR26","doi-asserted-by":"publisher","first-page":"2300","DOI":"10.1002\/1878-0261.12961","volume":"15","author":"C Engen","year":"2021","unstructured":"Engen C, Helles\u00f8y M, Grob T, Al Hinai A, Brendehaug A, Wergeland L, Bedringaas SL, Hovland R, Valk PJ, Gjertsen BT. FLT3-ITD mutations in acute myeloid leukaemia\u2013molecular characteristics, distribution and numerical variation. Mol Oncol. 2021;15(9):2300\u201317.","journal-title":"Mol Oncol"},{"issue":"8","key":"5009_CR27","doi-asserted-by":"publisher","first-page":"2421","DOI":"10.31557\/APJCP.2019.20.8.2421","volume":"20","author":"NM Kassem","year":"2019","unstructured":"Kassem NM, Medhat N, Kassem HA, El-Desouky MA. Chemotherapeutic resistance in Egyptian acute myeloid leukemia patients. Asian Pac J Cancer Prevention: APJCP. 2019;20(8):2421.","journal-title":"Asian Pac J Cancer Prevention: APJCP"},{"issue":"9","key":"5009_CR28","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1038\/s41577-023-00837-1","volume":"23","author":"M Colonna","year":"2023","unstructured":"Colonna M. The biology of TREM receptors. Nat Rev Immunol. 2023;23(9):580\u201394.","journal-title":"Nat Rev Immunol"},{"issue":"1","key":"5009_CR29","doi-asserted-by":"publisher","first-page":"242","DOI":"10.7150\/ijbs.77304","volume":"19","author":"WJ Zhong","year":"2023","unstructured":"Zhong WJ, Liu T, Yang HH, Duan JX, Yang JT, Guan XX, Xiong JB, Zhang YF, Zhang CY, Zhou Y, Guan CX. TREM-1 governs NLRP3 inflammasome activation of macrophages by firing up glycolysis in acute lung injury. Int J Biol Sci. 2023;19(1):242.","journal-title":"Int J Biol Sci"},{"issue":"3","key":"5009_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41569-019-0247-5","volume":"17","author":"S Jaiswal","year":"2020","unstructured":"Jaiswal S, Libby P. Clonal haematopoiesis: connecting ageing and inflammation in cardiovascular disease. Nat Reviews Cardiol. 2020;17(3):137\u201344.","journal-title":"Nat Reviews Cardiol"},{"key":"5009_CR31","doi-asserted-by":"crossref","unstructured":"Jalte M, Abbassi M, El Mouhi H, Belghiti HD, Ahakoud M, Bekkari H, JALTE M, ABBASSI M, EL MOUHI HI, AHAKOUD M, BEKKARI H. FLT3 mutations in acute myeloid leukemia: unraveling the molecular mechanisms and implications for targeted therapies. Cureus. 2023;15(9).","DOI":"10.7759\/cureus.45765"},{"issue":"04","key":"5009_CR32","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/BS9.0000000000000092","volume":"3","author":"H Shapoorian","year":"2021","unstructured":"Shapoorian H, Zalpoor H, Ganjalikhani-Hakemi M. The correlation between Flt3-ITD mutation in dendritic cells with TIM-3 expression in acute myeloid leukemia. Blood Sci. 2021;3(04):132\u20135.","journal-title":"Blood Sci"},{"issue":"12","key":"5009_CR33","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1200\/JCO.19.03011","volume":"38","author":"CS Hourigan","year":"2020","unstructured":"Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2020;38(12):1273\u201383.","journal-title":"J Clin Oncol"},{"key":"5009_CR34","doi-asserted-by":"crossref","unstructured":"Zhou X, Lin K, Fu L, Liu F, Lin H, Chen Y, Zhuang B, Liang H, Deng Q, Wang Z, Chen W. Overexpression of TREM1 is associated with the immune-suppressive microenvironment and unfavorable prognosis in pan-cancer. J Inflamm Res. 2023;31:1375\u201391.","DOI":"10.2147\/JIR.S398284"},{"issue":"3","key":"5009_CR35","first-page":"1552","volume":"111","author":"SP Whitman","year":"2008","unstructured":"Whitman SP, Ruppert AS, Radmacher MD, Mr\u00f3zek K, Paschka P, Langer C, Baldus CD, Wen J, Racke F, Powell BL, Kolitz JE. FLT3 D835\/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications. Blood. J Am Soc Hematol. 2008;111(3):1552\u20139.","journal-title":"J Am Soc Hematol"},{"issue":"3","key":"5009_CR36","doi-asserted-by":"publisher","first-page":"674","DOI":"10.20517\/cdr.2023.39","volume":"6","author":"L Gurska","year":"2023","unstructured":"Gurska L, Gritsman K. Unveiling T cell evasion mechanisms to immune checkpoint inhibitors in acute myeloid leukemia. Cancer Drug Resist. 2023;6(3):674.","journal-title":"Cancer Drug Resist"},{"issue":"15","key":"5009_CR37","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.3390\/cancers16152615","volume":"16","author":"DJ Chandra","year":"2024","unstructured":"Chandra DJ, Alber B, Saultz JN. The immune resistance signature of acute myeloid leukemia and current immunotherapy strategies. Cancers. 2024;16(15):2615.","journal-title":"Cancers"},{"issue":"3","key":"5009_CR38","doi-asserted-by":"publisher","first-page":"904","DOI":"10.3390\/cancers4030904","volume":"4","author":"E Ballabio","year":"2012","unstructured":"Ballabio E, Milne TA. Molecular and epigenetic mechanisms of MLL in human leukemogenesis. Cancers. 2012;4(3):904\u201344.","journal-title":"Cancers"},{"issue":"53","key":"5009_CR39","doi-asserted-by":"publisher","first-page":"90614","DOI":"10.18632\/oncotarget.21598","volume":"8","author":"C Dafflon","year":"2017","unstructured":"Dafflon C, Tiedt R, Schwaller J. Targeting multiple nodes of MLL complexes to improve leukemia therapy. Oncotarget. 2017;8(53):90614.","journal-title":"Oncotarget"},{"key":"5009_CR40","doi-asserted-by":"crossref","unstructured":"Li C, Cai C, Xu D, Chen X, Song J. TREM1: Activation, signaling, cancer and therapy. Pharmacol Res. 2024;13:107212.","DOI":"10.1016\/j.phrs.2024.107212"},{"issue":"1","key":"5009_CR41","first-page":"275760","volume":"2013","author":"U Testa","year":"2013","unstructured":"Testa U, Pelosi E. The impact of FLT3 mutations on the development of acute myeloid leukemias. Leuk Res Treat. 2013;2013(1):275760.","journal-title":"Leuk Res Treat"},{"issue":"8","key":"5009_CR42","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.3324\/haematol.2017.171819","volume":"102","author":"IZ Uras","year":"2017","unstructured":"Uras IZ, Bellutti F, Sexl V. p27 in FLT3-driven acute myeloid leukemia: many roads lead to ruin. Haematologica. 2017;102(8):1299.","journal-title":"Haematologica"},{"issue":"7633","key":"5009_CR43","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1038\/nature20598","volume":"540","author":"SW Ng","year":"2016","unstructured":"Ng SW, Mitchell A, Kennedy JA, Chen WC, McLeod J, Ibrahimova N, Arruda A, Popescu A, Gupta V, Schimmer AD, Schuh AC. A 17-gene stemness score for rapid determination of risk in acute leukaemia. Nature. 2016;540(7633):433\u20137.","journal-title":"Nature"},{"issue":"20","key":"5009_CR44","first-page":"2296","volume":"136","author":"KD Kokkaliaris","year":"2020","unstructured":"Kokkaliaris KD, Kunz L, Cabezas-Wallscheid N, Christodoulou C, Renders S, Camargo F, Trumpp A, Scadden DT, Schroeder T. Adult blood stem cell localization reflects the abundance of reported bone marrow niche cell types and their combinations. Blood J Am Soc Hematol. 2020;136(20):2296\u2013307.","journal-title":"Blood J Am Soc Hematol"},{"issue":"6","key":"5009_CR45","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1111\/bjh.16345","volume":"188","author":"JG Gribben","year":"2020","unstructured":"Gribben JG. Practical management of tumour lysis syndrome in venetoclax-treated patients with chronic lymphocytic leukaemia. Br J Haematol. 2020;188(6):844\u201351.","journal-title":"Br J Haematol"},{"key":"5009_CR46","doi-asserted-by":"publisher","first-page":"6346","DOI":"10.1182\/blood-2023-190244","volume":"142","author":"M Babcook","year":"2023","unstructured":"Babcook M, Lozanski G, Wall SA. CD123 As a Therapeutic Target in Accelerated and Blast Phase Myeloproliferative Neoplasms (MPNs). Blood. 2023;142:6346.","journal-title":"Blood"},{"issue":"7104","key":"5009_CR47","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nature04980","volume":"442","author":"AV Krivtsov","year":"2006","unstructured":"Krivtsov AV, Twomey D, Feng Z, Stubbs MC, Wang Y, Faber J, Levine JE, Wang J, Hahn WC, Gilliland DG, Golub TR. Transformation from committed progenitor to leukaemia stem cell initiated by MLL\u2013AF9. Nature. 2006;442(7104):818\u201322.","journal-title":"Nature"},{"issue":"2","key":"5009_CR48","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1038\/leu.2013.338","volume":"28","author":"MA Dawson","year":"2014","unstructured":"Dawson MA, Gudgin EJ, Horton SJ, Giotopoulos G, Meduri E, Robson S, Cannizzaro E, Osaki H, Wiese M, Putwain S, Fong CY. Recurrent mutations, including NPM1c, activate a BRD4-dependent core transcriptional program in acute myeloid leukemia. Leukemia. 2014;28(2):311\u201320.","journal-title":"Leukemia"},{"issue":"2","key":"5009_CR49","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1016\/j.ccr.2014.01.022","volume":"25","author":"A Puissant","year":"2014","unstructured":"Puissant A, Fenouille N, Alexe G, Pikman Y, Bassil CF, Mehta S, Du J, Kazi JU, Luciano F, R\u00f6nnstrand L, Kung AL. SYK is a critical regulator of FLT3 in acute myeloid leukemia. Cancer Cell. 2014;25(2):226\u201342.","journal-title":"Cancer Cell"}],"container-title":["Discover Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12672-026-05009-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05009-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12672-026-05009-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T06:03:21Z","timestamp":1778911401000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12672-026-05009-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5009"],"URL":"https:\/\/doi.org\/10.1007\/s12672-026-05009-w","relation":{},"ISSN":["2730-6011"],"issn-type":[{"value":"2730-6011","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"10 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board (IRB) of South Egypt Cancer Institute, Assiut University, Egypt (IRB No: 18 2025 743). All procedures performed in studies involving human participants were conducted in accordance with the ethical standards of the institutional research committee and with the 2013 revision of the Declaration of Helsinki and Good Clinical Practice guidelines. All methods were carried out in accordance with relevant guidelines and regulations. Informed written consent was obtained from all individual participants included in the study. For patients with impaired decision-making capacity, consent was obtained from legally authorized representatives in accordance with approved surrogate consent procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"740"}}